What is the significance of this 8-K/A filing for Amgen investors?

This filing is an amendment (8-K/A) to a previous 8-K report. Its primary purpose is to correct or add information to the original filing. Without the specific details of the amendment, it's difficult to determine its direct impact on investors. Investors would need to review the content of the amendment to understand what information was changed or added and its potential implications.

What information was originally reported in the December 30, 1994 8-K filing?

The provided content is only the 8-K/A filing and does not include the details of the original 8-K report filed on February 1, 1995. Therefore, the specific events or disclosures from the original report are not available for analysis.

Where can I find the full details of this 8-K/A filing?

The provided text is a directory listing from the SEC's EDGAR database. To access the full content of the 8-K/A filing, you would typically navigate to the SEC's EDGAR database online and search for Amgen Inc. (AMGN) filings around the date of February 1, 1995, looking for the 8-K/A document.

AMGN 8-K SEC Disclosure

Summary

This filing is an amendment to a previously submitted Current Report (8-K) for Amgen Inc. (AMGN), originally dated December 30, 1994, and filed on February 1, 1995. The amendment itself does not contain new substantive financial or operational details for investors to act upon. It primarily serves to correct or supplement information previously filed. Without the content of the original 8-K or the specific details of the amendment, it is impossible to provide insights into significant events, financial performance, or strategic changes that would directly impact investor decisions.

Key Highlights

1Amgen Inc. (AMGN) filed an amendment to a previous 8-K filing.
2The original event date associated with the filing was December 30, 1994.
3The amended filing was officially submitted to the SEC on February 1, 1995.
4This document is an amendment (8-K/A), indicating it modifies or supplements prior information.
5The filing relates to Amgen Inc.'s reporting obligations with the Securities and Exchange Commission.

AMGEN INC 8-K/A Report (Feb 2, 1995)

Summary

Key Highlights

Frequently Asked Questions